---
title: 'Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma:
  durable responses and treatment-free remissions'
date: '2024-04-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38662991/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240426181351&v=2.18.0.post9+e462414
source: Blood
description: In the phase-2 clinical trial (AIM) of venetoclax-ibrutinib, 24 patients
  with mantle cell lymphoma (MCL; 23 with relapsed/refractory [R/R] disease) received
  ibrutinib 560mg and venetoclax 400mg both once daily. High complete remission (CR)
  and measurable residual disease negative (MRD-negative) CR rates were previously
  reported. With median survivor follow-up now exceeding 7 years, we report long-term
  results. Treatment was initially continuous, with elective treatment interruption
  (ETI) ...
disable_comments: true
---
In the phase-2 clinical trial (AIM) of venetoclax-ibrutinib, 24 patients with mantle cell lymphoma (MCL; 23 with relapsed/refractory [R/R] disease) received ibrutinib 560mg and venetoclax 400mg both once daily. High complete remission (CR) and measurable residual disease negative (MRD-negative) CR rates were previously reported. With median survivor follow-up now exceeding 7 years, we report long-term results. Treatment was initially continuous, with elective treatment interruption (ETI) ...